Tetrahydro-indazole cannabinoid modulators

Abstract

This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.

1 - 17 . (canceled) 
   
   
       18 . A method for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of claim  1 . 
   
   
       19 . The method of  claim 18  wherein the cannabinoid receptor is a CB1 or CB2 receptor; and, the compound of claim  1  is an agonist, antagonist or inverse-agonist of the receptor. 
   
   
       20 . The method of  claim 18  wherein the syndrome, disorder or disease is related to appetite, metabolism, diabetes, glaucoma-associated intraocular pressure, social and mood disorders, seizures, substance abuse, learning, cognition or memory, organ contraction or muscle spasm, respiratory disorders, locomotor activity or movement disorders, immune and inflammation disorders, unregulated cell growth, pain management or neuroprotection. 
   
   
       21 . The method of  claim 18  wherein the effective amount of the compound of claim  1  is from about 0.001 mg/kg/day to about 300 mg/kg/day. 
   
   
       22 . The method of  claim 18  further comprising treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated appetite related, obesity related or metabolism related syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of claim  1 . 
   
   
       23 . The method of  claim 22  wherein the effective amount of the compound of claim  1  is from about 0.001 mg/kg/day to about 300 mg/kg/day. 
   
   
       24 . The method of  claim 18  further comprising the step of administering to the subject a combination product and/or therapy comprising an effective amount of a compound of claim  1  and a therapeutic agent. 
   
   
       25 . The method of  claim 24  wherein the therapeutic agent is an anticonvulsant or a contraceptive agent. 
   
   
       26 . The method of  claim 25  wherein the anticonvulsant is topiramate, analogs of topiramate, carbamazepine, valproic acid, lamotrigine, gabapentin, phenyloin and the like and mixtures or pharmaceutically acceptable salts thereof. 
   
   
       27 . The method of  claim 25  wherein the contraceptive agent is a progestin-only contraceptive, a contraceptive having a progestin component and an estrogen component, or an oral contraceptive optionally having a folic acid component. 
   
   
       28 . A method of contraception in a subject comprising the step of administering to the subject a composition, wherein the composition comprises a contraceptive and a CB1 receptor inverse-agonist or antagonist compound of claim  1 , wherein the composition reduces the urge to smoke in the subject and/or assists the subject in losing weight.